Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
Clinical trial NCT06631092 · RECRUITING
Trial details
- NCT number
- NCT06631092
- Sponsor
- NEC Bio B.V
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-20
- Primary completion
- 2027-12-31
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.